Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee
- 31 August 1995
- journal article
- Published by Elsevier in Clinical Therapeutics
- Vol. 17 (4), 602-612
- https://doi.org/10.1016/0149-2918(95)80037-9
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Worldwide experience with etodolac (Lodine®) 300 mg b.i.d. in the treatment of osteoarthritisRheumatology International, 1993
- Double-blind Comparison of etodolac and diclofenac in patients Mith rheumatoid arthritisCurrent Medical Research and Opinion, 1993
- Comparative Gastrointestinal Blood Loss Associated with Placebo, Aspirin, and Nabumetone as Assessed by Radiochromium (51Cr)The Journal of Clinical Pharmacology, 1989
- Recent clinical experience with etodolac in the treatment of osteoarthritis of the kneeClinical Rheumatology, 1989
- Endoscopy-controlled study of the safety of nabumetone compared with naproxen in arthritis therapyAmerican Journal Of Medicine, 1987
- Gastrointestinal Blood Loss in Arthritic Patients Receiving Chronic Dosing with Etodolac and PiroxicamThe American Journal of the Medical Sciences, 1986